Deals
Genzyme Rises Most Since Oct. 1999 on Sanofi Buyout Reports
This article is for subscribers only.
Genzyme Corp. shares increased the most in more than a decade in New York trading on media reports that Paris-based drugmaker Sanofi-Aventis SA made an offer to acquire the company.
The shares rose $10.32, or 19 percent, to $64.19, at 1:30 p.m. in Nasdaq Stock Market composite trading. The unsolicited offer for Cambridge, Massachusetts-based Genzyme was reported by CNBC and the Wall Street Journal.